Prevalence of antidepressants and biosimilars in elite sport

Gespeichert in:
Bibliographische Detailangaben
Deutscher übersetzter Titel:Vorherrschen von Antidepressiva und Biosimilars im Spitzensport
Autor:Machnik, M.; Sigmund, G.; Koch, A.; Thevis, Mario; Schänzer, Wilhelm
Erschienen in:Drug testing and analysis
Veröffentlicht:1 (2009), 6, S. 286–291, Lit.
Format: Literatur (SPOLIT)
Publikationstyp: Zeitschriftenartikel
Medienart: Gedruckte Ressource Elektronische Ressource (online)
Sprache:Englisch
ISSN:1942-7603, 1942-7611
DOI:10.1002/dta.49
Schlagworte:
Online Zugang:
Erfassungsnummer:PU200911006383
Quelle:BISp

Abstract

The use of prescribed antidepressants by athletes has not been restricted in human sports since 2003, after the antidepressants bupropion and amineptine were removed from the list of prohibited substances. Recent awareness of antidepressants has been stimulated by reports from the media concerning possiblemisuse of antidepressants among healthy athletes. The prevalence of antidepressants has been monitored over the past ten years with screening procedures routinely used by WADA-accredited laboratories. The growth in antidepressant use among athletes peaked in 2007 and 2008 after a modest increase over the first eight years of this survey. Pharmacy prescriptions for antidepressants in Germany did not show a correlated growth during this period. The increasing variety of antidepressant medications has led to a continued increase in the diversity of antidepressant substances used by athletes and the ‘normal’ population. The number of different sports affected by the presence of antidepressants has increased in the past decade, especially in endurance sports. The predominance of female antidepressant users in the normal population was reflected in the athletes’ group. We concluded from our results that the development of antidepressant prevalence in elite sports did not correlate with that among the general public in Germany. Verf.-Referat